Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Acute chest syndrome among hospitalized children with vaso-occlusive crisis: A nationwide study in the United States
source: American Society of Hematology
authors: Takuto Takahashi, Yusuke Okubo, Atsuhiko Handa, Scott T. Millersummary/abstract:
Background: Acute chest syndrome (ACS) remains a leading cause of mortality among children with sickle cell disease (SCD); overall, nearly 50% of ACS is diagnosed during hospitalizations for other complications including painful vaso-occlusive crises (VOC).
Methods: The present study assesses epidemiological features of children hospitalized with VOC and evaluates factors potentially associated with development of ACS utilizing the large national all-payer Kid’s Inpatient Database over a recent 9 year period. Records of children (age < 20 years) were reviewed from 2003, 2006, 2009, and 2012) and multivariable logistic regression was used to assess risk factors and adjust for patient and hospital characteristics.
Results: Total annual hospitalization rates with VOC were variable, ranging from 26.4 per 100,000 children in 2009 to 29.5 in 2012. Multivariable logistic regression analysis showed children age 5-9 years had 2.38 times higher odds of developing ACS than children age 15-19 (95%CI, 2.22 to 2.56). Comorbidity of asthma was a risk factor for ACS (OR, 1.44; 95%CI, 1.36 to 1.53). ACS was as common in Hb SC patients hospitalized for VOC as those with SS.
Conclusion: These data demonstrate that despite increasing use of hydroxyurea in children shown in other reports, there has been no reduction in hospitalization rate for pain, and even young children are at risk for ACS. Though de novo ACS is less common in Hb SC, vigilance and prophylactic measures are required for those hospitalized for pain. Further studies are needed to assess the efficacy of prophylactic interventions including bronchodilator therapy for asthmatics hospitalized for VOC.organization: SUNY Downstate Medical Center, Brooklyn, NY; UCLA Fielding School of Public Health, Los Angels, CA; National Research Institute for Child Health and Development, Tokyo, Japan; Massachusetts General Hospital for Children and Harvard Medical School, Boston, MA
Higher Executive Abilities Following a Blood Transfusion in Children and Young Adults With Sickle Cell DiseaseIndividuals with sickle cell disease (SC...
Prevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
New treatment plan leads to better pain control for acute sickle cell crisisThere’s new hope for the 70,000 to 80,...
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
Sickle cell trait may not contribute to stroke riskSickle cell trait may not be an ...
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.